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Immunologic Protection Afforded by Sun Screens
To the Editor:
With reference to the Section Editor’s note by Dr. Francis P. Gasparro
and the letter by Drs. Peter Wolf and Margaret Kripke published in
the Journal of Investigative Dermatology (110:183,184) concerning our
original paper in the June issue, we support our original conclusions
and disagree with the opinions expressed by these two groups. Both
groups have criticized our original paper for not calculating the immune
protection factor (IPF). Given the data we generated using five different
sun screens, we would certainly agree with both groups that to produce
an immunosuppression factor we would need to estimate the dose of
ultraviolet (UV) light needed to induce 50% immunosuppression with
and without the sun screens, and to divide the ISD50 obtained with
the sun screen by the ISD50 obtained without sun screens to give an IPF.
We feel, however, that it is very important to point out that an IPF
can in no way equal a sun protection factor (SPF). The erythemal
response and the immunosuppressive response in the skin caused by
UV radiation have very different cellular and molecular mechanisms
and almost certainly different dose–response curves. There is therefore
no way that one can directly compare SPF with IPF. Indeed, do we
really want another label on sun screens that will only confuse the user
further? We already have an SPF that many patients do not understand
and a number of very different ways that companies can choose from
when indicating UVA protection on pack labels, such as the star rating
seen in the U.K. Putting an IPF value as well on bottles would almost
certainly confuse the end user even further. We would emphasize that
with the potential to further cloud the issue, at no point did we try
to ascribe an IPF to the creams used in our study.
The major danger that we foresee is that if a sun screen protects
against UV erythema to a greater extent than it protects against the
immune response, then immunosuppression could result without any
evidence of clinical erythema. This could thus potentially increase the
risk of significant UV induced skin damage such as skin cancer, while
giving the user the false impression that they are protecting themselves
from this damage. The conclusion we drew from our original study
was that all the sun screens that we tested, which had SPF from 3.5
to 5.7, protected the skin immune system beyond the UV dose required
to exceed the SPF of the sun screen. That means that with a sun
screen of SPF 5, skin irradiated with five times the minimal erythema
dose showed no evidence of immunosuppression. Although the IPF is
of obvious scientific interest, the fact that sun blocks will protect
against erythema and immunosuppression to the same dose of UV
light is of far greater clinical importance.
We also feel it is important to point out that in further data that we
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have generated looking at test formulations of sun screens, we have
identified some formulations of sun screens that do not protect the
immune system to the SPF of the sun screen, and that in these
formulations there is a significant discrepancy between erythemal
protection and immunoprotection. The use of these sun screens
would therefore increase the potential risk of patients developing
immunosuppression related to UV exposure without visible signs of
erythema or sunburn.
There are obvious practical problems in developing an IPF using
the methodology in our paper. Our methodology has the advantage
of using a human system that avoids the inter species variation in
response to UV light and also ethical issues. It does, however, restrict
us in the number of experiments that can be performed. To assess the
IPF for each sun screen that we wish to test, we would require much
larger quantities of skin than we have access to and this would almost
certainly make the procedure impracticable. The technique does,
however, provide for a rapid, easy, reproducible, noninvasive, and
animal sparing technique that can reduce the concern that sun blocks
will protect the skin immune system to the UV irradiation dose that
is equivalent to the UV erythemal dose the patient can achieve using
the sun screens.
In Gasparro’s note there is also a comment about the sensitivity of
our assay compared with that of Cooper et al (1985). We would like
to point out that the study conducted by Cooper et al used the Phillips
FS20 light source that is now known to be contaminated with UVC
and this may contribute to its more significant immunosuppressive
effect. The Phillips FS20 also produces predominately short wavelength
UVB, whereas the light source we use, the Oriel Solar Simulator, does
provide a UV spectral output similar to natural sunlight. Cooper et al
also used different cell numbers in their mixed epidermal lymphocyte
reaction, and studies in our laboratory have shown that lowering the
number of stimulator epidermal cells and responder lymphocytes can
increase the sensitivity of the technique. It does not, however, alter
the end result and should therefore not affect the immunoprotection
afforded by using sun screens.
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